MCID: RSP019
MIFTS: 45

Respiratory Distress Syndrome in Premature Infants

Categories: Respiratory diseases, Rare diseases

Aliases & Classifications for Respiratory Distress Syndrome in Premature Infants

MalaCards integrated aliases for Respiratory Distress Syndrome in Premature Infants:

Name: Respiratory Distress Syndrome in Premature Infants 54 71 29
Hyaline Membrane Disease 56 71 69
Infant Acute Respiratory Distress Syndrome 56
Neonatal Respiratory Distress Syndrome 56
Respiratory Distress Syndrome, Newborn 69
Infant Respiratory Distress Syndrome 56
Rds in Prematurity 71
Infant Ards 56
Rds 71

Characteristics:

Orphanet epidemiological data:

56
infant acute respiratory distress syndrome
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal;

OMIM:

54
Miscellaneous:
onset at birth
may be associated with polymorphisms in some surfactant genes, including sftpa1 , sftpb , and sftpc

Inheritance:
isolated cases
multifactorial


HPO:

32
respiratory distress syndrome in premature infants:
Onset and clinical course congenital onset
Inheritance sporadic multifactorial inheritance


Classifications:

Orphanet: 56  
Rare respiratory diseases


External Ids:

OMIM 54 267450
Orphanet 56 ORPHA70587
UMLS via Orphanet 70 C0020192 C0035220 C0852283
ICD10 via Orphanet 34 P22.0
MedGen 40 C1968593
MeSH 42 D006819

Summaries for Respiratory Distress Syndrome in Premature Infants

OMIM : 54
The main cause of respiratory distress syndrome (RDS) in premature infants is a developmental deficiency of pulmonary surfactant. The frequency of RDS is inversely proportional to gestational age. However, not all infants born prematurely develop RDS, suggesting that there may be susceptibility factors. Because multiple factors can contribute to the pathogenesis of RDS specifically in premature infants, the etiology is considered to be multifactorial (summaries by Ramet et al., 2000; Clark and Clark, 2005). Pathogenic germline mutations in several genes involved in surfactant metabolism, including SFTPB (178640) and SFTPC (178620), can cause clinical features of respiratory distress syndrome in term neonates, children, and adults, disorders referred to as 'surfactant metabolism dysfunction' (see, e.g., SMDP1, 265120). Susceptibility to the development of RDS in premature infants may be associated with polymorphisms in surfactant genes, such as surfactant protein A1 (SFTPA1; 178630), SFTPB, and SFTPC (see MOLECULAR GENETICS). (267450)

MalaCards based summary : Respiratory Distress Syndrome in Premature Infants, also known as hyaline membrane disease, is related to choreoathetosis, hypothyroidism, and neonatal respiratory distress and restrictive dermopathy, lethal, and has symptoms including premature birth, respiratory distress and tachypnea. An important gene associated with Respiratory Distress Syndrome in Premature Infants is SFTPB (Surfactant Protein B), and among its related pathways/superpathways are Metabolism of proteins and Diseases of metabolism. The drugs Beractant and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotype is respiratory system.

UniProtKB/Swiss-Prot : 71 Respiratory distress syndrome in premature infants: A lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high- permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'.

Wikipedia : 72 Infant respiratory distress syndrome (IRDS), also called neonatal respiratory distress... more...

Related Diseases for Respiratory Distress Syndrome in Premature Infants

Diseases related to Respiratory Distress Syndrome in Premature Infants via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
id Related Disease Score Top Affiliating Genes
1 choreoathetosis, hypothyroidism, and neonatal respiratory distress 11.7
2 restrictive dermopathy, lethal 11.5
3 reticular dysgenesis 11.4
4 newborn respiratory distress syndrome 11.4
5 respiratory distress syndrome, infant 11.0
6 adult respiratory distress syndrome 10.8
7 renal hypodysplasia/aplasia 2 10.8
8 refsum disease 10.8
9 renal hypodysplasia/aplasia 1 10.8
10 interstitial emphysema 10.1
11 patent ductus arteriosus 10.0
12 bronchopulmonary dysplasia 9.8
13 tricuspid valve prolapse 9.7 ABCA3 SFTPC
14 coronary stenosis 9.7 SFTPB SFTPC
15 intestinal atresia 9.7 SFTPB SFTPC
16 neurotrophic keratoconjunctivitis 9.7 SFTPB SFTPC
17 adenocarcinoid tumor 9.7 SFTPB SFTPC
18 aspiration pneumonia 9.7
19 chorioamnionitis 9.7
20 pneumothorax 9.7
21 neonatal jaundice 9.7
22 pneumonia 9.7
23 skull base neoplasm 9.6 SFTPB SFTPC
24 middle lobe syndrome 9.5 SFTPA1 SFTPC
25 anogenital venereal wart 9.5 SFTPB SFTPC
26 hartnup disorder 9.5 SFTPB SFTPC
27 renal oncocytoma 9.3 SFTPA1 SFTPC
28 common wart 9.3 ABCA3 SFTPB SFTPC
29 osteoarthritis 9.3 ABCA3 SFTPB SFTPC
30 granulomatous orchitis 9.2 ABCA3 SFTPB SFTPC
31 adenoid squamous cell carcinoma 9.2 SFTPB SFTPC
32 anonychia with flexural pigmentation 8.7 ABCA3 SFTPA1 SFTPB SFTPC
33 anoxia 8.7 ABCA3 SFTPA1 SFTPB SFTPC
34 radioulnar synostosis with amegakaryocytic thrombocytopenia 8.7 ABCA3 SFTPA1 SFTPB SFTPC
35 bullous skin disease 8.6 ABCA3 SFTPA1 SFTPB SFTPC
36 diamond-blackfan anemia 3 8.6 ABCA3 SFTPA1 SFTPB SFTPC

Graphical network of the top 20 diseases related to Respiratory Distress Syndrome in Premature Infants:



Diseases related to Respiratory Distress Syndrome in Premature Infants

Symptoms & Phenotypes for Respiratory Distress Syndrome in Premature Infants

Symptoms via clinical synopsis from OMIM:

54

Respiratory:
dyspnea
tachypnea
respiratory insufficiency, neonatal

Prenatal Manifestations- Delivery:
premature delivery, less than 37 weeks' gestation

Respiratory- Lung:
atelectasis
decreased surfactant
lung edema
fibrin-rich alveolar deposits, 'hyaline membranes'
diffuse reticulogranular pattern seen on chest radiograph


Clinical features from OMIM:

267450

Human phenotypes related to Respiratory Distress Syndrome in Premature Infants:

32 (show all 7)
id Description HPO Frequency HPO Source Accession
1 premature birth 32 HP:0001622
2 respiratory distress 32 HP:0002098
3 tachypnea 32 HP:0002789
4 atelectasis 32 HP:0100750
5 disseminated intravascular coagulation 32 HP:0005521
6 neonatal respiratory distress 32 HP:0002643
7 pulmonary edema 32 HP:0100598

UMLS symptoms related to Respiratory Distress Syndrome in Premature Infants:


cheyne-stokes respiration, coughing, dyspnea, hemoptysis, hoarseness, respiratory distress

MGI Mouse Phenotypes related to Respiratory Distress Syndrome in Premature Infants:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 8.92 ABCA3 SFTPA1 SFTPB SFTPC

Drugs & Therapeutics for Respiratory Distress Syndrome in Premature Infants

Drugs for Respiratory Distress Syndrome in Premature Infants (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Beractant Approved Phase 4,Phase 2,Phase 3,Phase 1 108778-82-1
2
Budesonide Approved Phase 4 51333-22-3 63006 5281004
3
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
4
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
5
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
6
Carbon monoxide Approved Phase 4 630-08-0 281
7 Poractant alfa Approved Phase 4,Phase 2,Phase 3 129069-19-8
8
Remifentanil Approved Phase 4 132875-61-7 60815
9 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
10 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Autonomic Agents Phase 4,Phase 3,Phase 2
13 Bronchodilator Agents Phase 4,Phase 3
14 glucocorticoids Phase 4,Phase 3,Phase 2
15 Hormone Antagonists Phase 4,Phase 3,Phase 2
16 Hormones Phase 4,Phase 3,Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Pulmonary Surfactants Phase 4,Phase 3,Phase 2,Phase 1
20 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Neurotransmitter Agents Phase 4,Phase 3
22 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
23 Anesthetics Phase 4,Phase 3
24 Anesthetics, General Phase 4,Phase 3
25 Anesthetics, Intravenous Phase 4,Phase 3
26 Central Nervous System Depressants Phase 4,Phase 3
27 Hypnotics and Sedatives Phase 4,Phase 3
28 Betamethasone benzoate Phase 4,Phase 2,Phase 3
29 Betamethasone sodium phosphate Phase 4,Phase 2,Phase 3
30 Betamethasone Valerate Phase 4,Phase 2,Phase 3 2152-44-5
31 Betamethasone-17,21-dipropionate Phase 4,Phase 2,Phase 3
32 Antimetabolites Phase 4
33 Analgesics, Opioid Phase 4
34 Narcotics Phase 4
35
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
36
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
37
Ibuprofen Approved Phase 2, Phase 3,Phase 1 15687-27-1 3672
38
Nitric Oxide Approved Phase 3,Phase 2 10102-43-9 145068
39
Calfactant Approved Phase 3 183325-78-2
40
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
41
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
42 Adjuvants, Anesthesia Phase 3
43 Anesthetics, Dissociative Phase 3
44 Anti-Anxiety Agents Phase 3
45 Excitatory Amino Acid Antagonists Phase 3
46 Excitatory Amino Acids Phase 3
47 GABA Agents Phase 3
48 GABA Modulators Phase 3
49 Psychotropic Drugs Phase 3
50 Tranquilizing Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 165)

id Name Status NCT ID Phase Drugs
1 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
2 Efficacy Evaluation of Surfactant Administration Via Laryngeal Mask Airway Unknown status NCT01173237 Phase 4
3 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
4 Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams Unknown status NCT00277030 Phase 4 Surfactant
5 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
6 Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide Completed NCT01923844 Phase 4 exogenous surfactant
7 Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study Completed NCT00501982 Phase 4 Poractant alfa (Curosurf®)
8 Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress Completed NCT00486850 Phase 4
9 Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants Completed NCT01741129 Phase 4
10 Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome Recruiting NCT02164734 Phase 4 remifentanil
11 Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
12 NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome Not yet recruiting NCT02901652 Phase 4
13 SLI MANEUVER and RESPIRATORY MORBIDITIES Not yet recruiting NCT02887924 Phase 4
14 Intratracheal Budesonide/Surfactant Prevents BPD Not yet recruiting NCT03275415 Phase 4 budesonide;Saline
15 Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
16 Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants Terminated NCT00146497 Phase 4 Budesonide-Surfactant
17 Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
18 Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room Unknown status NCT01517828 Phase 3 Sedation by ketamine;Sedation with Midazolam
19 NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome) Completed NCT02259400 Phase 2, Phase 3
20 Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome Completed NCT00244101 Phase 3 PS Group;ISX Group
21 A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants Completed NCT02305160 Phase 2, Phase 3 Butantan;Control
22 A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants Completed NCT01709409 Phase 3 Curosurf-Group1;BLES-group 2
23 Very Early Surfactant and NCPAP for Premature Infants With RDS Completed NCT00563641 Phase 3
24 Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants Completed NCT00152542 Phase 3 Inhaled nitric oxide;Placebo
25 High Frequency Ventilation in Premature Infants (HIFI) Completed NCT00000567 Phase 3
26 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Completed NCT00569530 Phase 3 Infasurf (ONY Inc.);Sham
27 Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome Completed NCT01203358 Phase 2, Phase 3 Exosurf;Survanta
28 Dexamethasone Therapy in VLBW Infants at Risk of CLD Completed NCT00011362 Phase 3 Dexamethasone Early;Dexamethasone Late
29 Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome Recruiting NCT03231735 Phase 2, Phase 3
30 Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants. Recruiting NCT02056223 Phase 2, Phase 3 Intravenous paracetamol;Intravenous ibuprofen
31 Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity? Not yet recruiting NCT02939742 Phase 2, Phase 3 Betamethasone;Placebo
32 Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates Not yet recruiting NCT02774044 Phase 2, Phase 3 Cadisurf;Survanta
33 Will CPAP Reduce Length Of Respiratory Support In Premature Infants? Terminated NCT00486395 Phase 3
34 Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants Terminated NCT00005774 Phase 3 Early surfactant;Standard practice
35 Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure Terminated NCT00016523 Phase 3 Inhaled nitric oxide;Placebo
36 Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE) Terminated NCT00005777 Phase 3 Dexamethasone;Placebo
37 Nifedipine Treatment in Preterm Labor Withdrawn NCT01314859 Phase 3 Nifedipine;Atosiban
38 Effectiveness of ACS in Extreme Preemies Withdrawn NCT02351310 Phase 3 Betamethasone
39 Efficacy of Antenatal Steroids in Reducing Respiratory Morbidities in Late Preterm Infants Unknown status NCT01206946 Phase 2 Betamethasone
40 Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS Unknown status NCT01723683 Phase 2 Surfactant
41 Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants Unknown status NCT01149564 Phase 1, Phase 2 iv ibuprofen;oral ibuprofen
42 Effect of Antenatal Corticosteroids in Late Preterm Unknown status NCT01710384 Phase 2 betamethasone
43 Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS) Completed NCT01473264 Phase 1, Phase 2 recombinant human CC10 (rhCC10);recombinant human CC10 (rhCC10);placebo
44 High-frequency Oscillatory Ventilation (HFOV) in Preterm Infants With Severe Respiratory Distress Syndrome (RDS) Completed NCT01496508 Phase 2
45 NCPAP + Heliox as a Treatment for Infant Respiratory Distress Syndrome (RDS) Completed NCT01383850 Phase 2
46 Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial Completed NCT01242462 Phase 1, Phase 2
47 Dexamethasone for Preterm Labour Completed NCT01697098 Phase 2 Dexamethasone 24 hours;Dexamethasone 12
48 Trial II of Lung Protection With Azithromycin in the Preterm Infant Completed NCT00319956 Phase 2 Azithromycin;D5W
49 Ventilatory Management of the Preterm Neonate in the Delivery Room Completed NCT01255826 Phase 2
50 A Double Blind, Randomized, Controlled Study to Compare CHF 5633 (Synthetic Surfactant) and Poractant Alfa in RDS Recruiting NCT02452476 Phase 2 CHF5633;Poractant alfa

Search NIH Clinical Center for Respiratory Distress Syndrome in Premature Infants

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Respiratory Distress Syndrome in Premature Infants

Genetic tests related to Respiratory Distress Syndrome in Premature Infants:

id Genetic test Affiliating Genes
1 Respiratory Distress Syndrome in Premature Infants 29

Anatomical Context for Respiratory Distress Syndrome in Premature Infants

MalaCards organs/tissues related to Respiratory Distress Syndrome in Premature Infants:

39
Lung, Testes, Bone, Thyroid, Placenta

Publications for Respiratory Distress Syndrome in Premature Infants

Articles related to Respiratory Distress Syndrome in Premature Infants:

(show all 21)
id Title Authors Year
1
Different ventilation modes combined with ambroxol in the treatment of respiratory distress syndrome in premature infants. ( 28352342 )
2017
2
The role of surfactant and non-invasive mechanical ventilation in early management of respiratory distress syndrome in premature infants. ( 25124970 )
2014
3
Early surfactant for respiratory distress syndrome in premature infants. ( 24049954 )
2013
4
Lucinactant for the prevention of respiratory distress syndrome in premature infants. ( 23473590 )
2013
5
Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants. ( 16698258 )
2007
6
A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants, by G. C. Liggins, MB, PhD, FRCOG, and R. N. Howie, MB, MRACP, Pediatrics, 1972;50:515-525. ( 9651447 )
1998
7
Antenatal ambroxol treatment does not prevent the respiratory distress syndrome in premature infants. ( 9177984 )
1997
8
Prenatal ritodrine administration and the incidence of respiratory distress syndrome in premature infants. ( 9134506 )
1997
9
Synthetic surfactant for rescue treatment of respiratory distress syndrome in premature infants weighing from 700 to 1350 grams: impact on hospital resource use and charges. ( 7815233 )
1995
10
A preliminary report of prenatal cocaine exposure and respiratory distress syndrome in premature infants. ( 2035498 )
1991
11
Exogenous surfactant for treatment of respiratory distress syndrome in premature infants. ( 1973717 )
1990
12
Effects of postnatal aminophylline on the course of respiratory distress syndrome in premature infants. ( 3731212 )
1986
13
The prevention of respiratory distress syndrome in premature infants: efficacy of antenatal aminophylline treatment versus prenatal glucocorticoid administration. ( 6739183 )
1984
14
An analysis of the factors associated with respiratory distress syndrome in premature infants whose mothers had been given dexamethasone therapy. ( 7426540 )
1980
15
Antepartum aminophylline treatment for prevention of the respiratory distress syndrome in premature infants. ( 582496 )
1979
16
Relation of amniotic fluid lecithin/sphingomyelin ratio and fetal asphyxia to respiratory distress syndrome in premature infants. ( 657031 )
1978
17
Effect of antenatal glucocorticoid administered in a single dose on the incidence of respiratory distress syndrome in premature infants. ( 581109 )
1978
18
Patent ductus arteriosus ligation and respiratory distress syndrome in premature infants. ( 973762 )
1976
19
Prevention of the respiratory distress syndrome in premature infants by antepartum glucocorticoid therapy. ( 943175 )
1976
20
Ligation of patent ductus arteriosus for persistent respiratory distress syndrome in premature infants. ( 4843981 )
1974
21
A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. ( 4561295 )
1972

Variations for Respiratory Distress Syndrome in Premature Infants

ClinVar genetic disease variations for Respiratory Distress Syndrome in Premature Infants:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 BRAF NM_004333.4(BRAF): c.1502A> G (p.Glu501Gly) single nucleotide variant Pathogenic/Likely pathogenic rs180177039 GRCh37 Chromosome 7, 140477806: 140477806

Expression for Respiratory Distress Syndrome in Premature Infants

Search GEO for disease gene expression data for Respiratory Distress Syndrome in Premature Infants.

Pathways for Respiratory Distress Syndrome in Premature Infants

GO Terms for Respiratory Distress Syndrome in Premature Infants

Cellular components related to Respiratory Distress Syndrome in Premature Infants according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.62 ABCA3 SFTPA1 SFTPB SFTPC
2 endoplasmic reticulum membrane GO:0005789 9.54 SFTPA1 SFTPB SFTPC
3 multivesicular body lumen GO:0097486 9.26 SFTPB SFTPC
4 alveolar lamellar body GO:0097208 9.16 ABCA3 SFTPB
5 clathrin-coated endocytic vesicle GO:0045334 9.13 SFTPA1 SFTPB SFTPC
6 lamellar body GO:0042599 8.8 SFTPA1 SFTPB SFTPC

Biological processes related to Respiratory Distress Syndrome in Premature Infants according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lipid transport GO:0006869 9.16 ABCA3 SFTPA1
2 respiratory gaseous exchange GO:0007585 9.13 SFTPA1 SFTPB SFTPC
3 cellular protein metabolic process GO:0044267 8.92 ABCA3 SFTPA1 SFTPB SFTPC

Molecular functions related to Respiratory Distress Syndrome in Premature Infants according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lipid transporter activity GO:0005319 8.62 ABCA3 SFTPA1

Sources for Respiratory Distress Syndrome in Premature Infants

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....